| [1] |
. Liver Int，2021，41（4）：683-691.
|
| [2] |
Fan LY，Sweet DR，Prosdocimo DA，et al. Muscle Krüppel-like factor 15 regulates lipid flux and systemic metabolic homeostasis［J］. J Clin Invest，2021，131（4）：e139496.
|
| [3] |
Moon JS，Yoon JS，Won KC，et al. The role of skeletal muscle in development of nonalcoholic fatty liver disease［J］. Diabetes Metab J，2013，37（4）：278-285.
|
| [4] |
Srikanthan P，Hevener AL，Karlamangla AS. Sarcopenia exacerbates obesity-associated insulin resistance and dysglycemia：findings from the National Health and Nutrition Examination Survey III［J］. PLoS One，2010，5（5）：e10805.
|
| [5] |
Huang JS，Glauber M，Qiu ZH，et al. The influence of skeletal muscle on the regulation of liver：body mass and liver regeneration［J］. Am J Pathol，2012，180（2）：575-582.
|
| [6] |
Van Der Windt DJ，Sud V，Zhang HJ，et al. The effects of physical exercise on fatty liver disease［J］. Gene Expr，2018，18（2）：89-101.
|
| [7] |
Takahashi H，Kotani K，Tanaka K，et al. Therapeutic approaches to nonalcoholic fatty liver disease：exercise intervention and related mechanisms［J］. Front Endocrinol （Lausanne），2018，9：588-604.
|
| [8] |
Duan D，Goemans N，Takeda S，et al. Duchenne muscular dystrophy［J］. Nat Rev Dis Primers，2021，7（1）：13-32.
|
| [9] |
Cirak S，Feng L，Anthony K，et al. Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy［J］. Mol Ther，2012，20（2）：462-467.
|
| [10] |
Nathwani RA，Pais S，Reynolds TB，et al. Serum alanine aminotransferase in skeletal muscle diseases［J］. Hepatology，2005，41（2）：380-382.
|
| [11] |
White Z，Hakim CH，Theret M，et al. High prevalence of plasma lipid abnormalities in human and canine Duchenne and Becker muscular dystrophies depicts a new type of primary genetic dyslipidemia［J］. J Clin Lipidol，2020，14（4）：459-469.
|
| [12] |
Jeon BN，Kim YS，Choi WI，et al. Kr-pok increases FASN expression by modulating the DNA binding of SREBP-1c and Sp1 at the proximal promoter［J］. J Lipid Res，2012，53（4）：755-766.
|
| [13] |
Wakil SJ，Abu-Elheiga LA. Fatty acid metabolism：target for metabolic syndrome［J］. J Lipid Res，2009，50 SupplS：138-143.
|
| [14] |
Mei Lk，Wei QQ，Zhang HB，et al. Research progress in acetyl-CoA carboxylase inhibitors［J］ J China Pharm Univ（中国药科大学学报），2019，50（3）：253-264.
|
| [15] |
Abu-Elheiga L，Almarza-Ortega DB，Baldini A，et al. Human acetyl-CoA carboxylase 2. Molecular cloning，characterization，chromosomal mapping，and evidence for two isoforms［J］. J Biol Chem，1997，272（16）：10669-10677.
|
| [16] |
Chen GX，Liang GS，Ou J，et al. Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver［J］. Proc Natl Acad Sci U S A，2004，101（31）：11245-11250.
|
| [17] |
Schomaker S，Potter D，Warner R，et al. Serum glutamate dehydrogenase activity enables early detection of liver injury in subjects with underlying muscle impairments［J］. PLoS One，2020，15（5）：e0229753.
|
| [18] |
Wagner KR. The elusive promise of myostatin inhibition for muscular dystrophy［J］. Curr Opin Neurol，2020，33（5）：621-628.
|
| [19] |
Dasarathy S. Cause and management of muscle wasting in chronic liver disease［J］. Curr Opin Gastroenterol，2016，32（3）：159-165.
|
| [20] |
Garcia PS，Cabbabe A，Kambadur R，et al. Brief-reports：elevated myostatin levels in patients with liver disease：a potential contributor to skeletal muscle wasting［J］. Anesth Analg，2010，111（3）：707-709.
|
| [21] |
Hanai T，Shiraki M，Ohnishi S，et al. Rapid skeletal muscle wasting predicts worse survival in patients with liver cirrhosis［J］. Hepatol Res，2016，46（8）：743-751.
|
下载:
